Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Completed · Not applicable
Conditions studied: Insulin Resistance, Hypertriglyceridemia
In brief
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatment for this a medication called fenofibrate, another medication that can improve insulin resistance is rosiglitazone, a third treatment known to improve insulin resistance an decrease triglycerides is weight loss. In this study insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of these treatments and results of insulin sensitivity and cardiac risk profiles will be compared at the end of the study.
Key facts
- Study ID
- NCT00186537
- Run by
- Stanford University
- People needed
- 47
- Starts
- 2003-09-01
- Expected to finish
- 2008-09-01
- Last updated by the study team
- 2017-01-12
Who can join
Age: 30 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Insulin Resistant Triglyceride 150 mg/dL or greater or triglyceride HDL-C ratio 3 or greater BMI 25-35
You may not qualify if…
- Diabetes Mellitus History of gall stones History of CHF History of CAD Severe anemia,kidney, or liver disease
Where it is running
- Stanford University Medical Center — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.